Ofer Talmor Israel

AlephBot is developing a new paradigm in healthcare, the procedure monitor.
The solution helps medical teams maximize treatment efficiency during and after medical procedures (e.g., resuscitation, labor, general anesthesia). It provides the team members with valuable real-time information that is adaptive to their actions and to the procedure’s stage, even if they are under pressure or can’t recall procedure steps by heart. AlephBot also automatically documents the medical procedure, which serves for both medical education and medico-legal purposes.

** AlephBot uniqueness **
We capture the human perspective of a procedure by analyzing the relevant info from the on-going structural medical conversation. We add this layer to the data collected from other sources.
Therefore, we gain higher accuracy of the analyzed medical situation, which enables us to identify the procedure stage and provide meaningful info, in real-time.

** Status **
AlephBot is developing its core technology. The company, pre-seed funded, was selected to the DRIVE accelerator at the Technion (Israel institute of Technology), and received grants from the Israel Innovation Authority.
AlephBot cooperates with big and small hospitals from day one. This serves our intention to increase treatment efficiency both in mega-hospitals in big cities and in smaller ones in the periphery and rural areas.

AlephBot is active in its target markets (Germany, France, Italy and the US) and won several national and international (France, Germany, Denmark) events and competitions. The company is still not active in China - an opportunity!

** Next steps **
We are currently looking for seed investment to finalize our core technology development and bring the product to clinical trial stage in two years. Sales are planned in three years, post regulation clearance.

Company Size (Fulltime employees)
Year of foundation
2017
Looking for
Please specify your partnering goal
Fundraising and set the ground for future business in China.
Funding Status
On going seed round
Now raising (In USD)
2,000,000
Headquartner in China
Plan in China
We see great potential in using AlephBot in China, as it could help with the following challenges:* Increase rural medicine level, supporting medical caregivers in rural areas during treatment (caregivers are with limited knowledge, not up-to-date). * Increase treatment efficiency in big hospitals of big cities. These are high-standard hospitals, that use “state of the art” solutions like AlephBot, for better treatment, cost saving and patient satisfaction.
Slides Deck
(pdf, 305.3KB)
Ofer Talmor
AlephBot
CEO and co-founder 
Functionality

Jason Tang China

• EpimAb Biotherapeutics is a biopharmaceutical R&D company based in Shanghai creating a pipeline of novel biologics focused around oncology and other disease areas of high value to patients using its a proprietary, and unique technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). Company’s pioneer product EMB-01 is a bispecific antibody based on FIT-Ig platform targeting EGFR as well as c-MET, currently is in being investigated for treatment of solid tumors in global Phase I/II clinical trial. EpimAb aims to commercialize its FIT-Ig technology as broadly as possible and maximize the number of programs based on the platform. Further information please visit www.epimab.com
• 岸迈生物科技有限公司是一家总部位于上海的生物制药研发公司。公司基于自主研发的FIT-Ig®双特异性抗体平台技术,聚焦于肿瘤IO领域的创新药品开发。公司的先锋产品EMB-01是一种基于FIT-Ig®平台的双特异性抗体,针对EGFR和c-MET靶点,目前正在进行针对实体瘤的全球I/II期临床试验。岸迈生物的目标是尽可能广泛地将其FIT-Ig®技术商业化,并最大限度地拓展基于该平台的新药开发。更多信息,请访问公司官网www.epimab.com。
Website:
www.epimab.com
Year of foundation
2016
Looking for
Headquartner in China
Jason Tang
EpimAb Biotherapeutics
BD head of China 
Functionality

Richard Tao China

Fenglin Biomedical Center (BioFM) is an innovation platform based in Xuhui Shanghai, which functions as the China soft-landing gateway for oversea bio-medical companies. It provides working spaces in downtown area in a flexible manner and helps clients increase their business value with professional services and by leveraging innovative resources including academics, hospitals, industries and venture capitals in the region. Different from the traditional accelerators and incubators, BioFM aims to be a boutique and unique service provider especially for bio-medical entrepreneurs, doctors, and scientists, while helping overseas companies and start-ups to develop their business in China quicker and better
Company Size (Fulltime employees)
Please specify your partnering goal
Attract innovative biomedical startups and established companies into Shanghai Fenglin Life Sciences Park
Headquartner in China
Your Service Name
Life science cluster & healthtech incubator in central Shanghai, we can offer China insight and China landing platform
Target Client Type
Clients that are interested to expand into China
Shanghai Fenglin Biomedical Development Co. Ltd
Mr / Project Manager 
Functionality

Kun Tao United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Mybiogate Inc.
Functionality

Lu Tian China

Founded in 1990, Zhejiang Jingxin Pharmaceutical Co., Ltd. is a listed pharmaceutical company integrating R&D, production and sales.
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, provincial academician expert workstation, provincial high-tech enterprise R & D center, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park.
Jingxin Pharmaceutical adheres to the mission of meticulously guarding health and is committed to becoming a front runner in neurological and cardiovascular therapy areas in China.
No. 70 pharmaceutical companies in China.
Looking for
Headquartner in China
Shanghai Jingxin Biology&Pharmaceutical Co,.LTD
Project Manager 
Functionality

Jessie Tong Singapore

Santen Pharmaceutical Co., Ltd. (参天製薬株式会社), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.

We are looking for investment and licensing opportunites in the ophthalmology field. 

Company Size (Fulltime employees)
Stock Market and Ticker/Symbol/Number
TYO: 4536
Please specify your partnering goal
Investment and in-licensing opportunities in ophthalmology field
Headquartner in China
Biotech/Pharma Asset Stage
Medtech Development Stage
Investment Focus
Ophthalmology
Santen Pharmaceutical
LinkedIn logo Regional Venture Capital Manager 
Functionality

Kathy Tong China

to promote the business cooperation between Israel and Southwest China
Company Size (Fulltime employees)
Please specify your partnering goal
looking for Chinese companies and investors have an interest in IL technologies
Headquartner in China
Biotech/Pharma Asset Stage
Medtech Development Stage
Israel Foreign Trade Administration
Trade Director 

Mr. Jake Townsend United States

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.
Website:
celumigen.com
Company Size (Fulltime employees)
Looking for
Please specify your partnering goal
Strategic investment/ partnership
Headquartner in China
Plan in China
The Chinese market for our therapeutics pipeline is among the largest and most promising in the world. Greater than 500 Million Chinese people suffer from Cutaneous viral warts, with no approved therapies and none that eradicate warts. We plan on capturing this market and growing in the Chinese pharmaceutical market, and from there, growing into the rest of the world. China represents a vital vantage point to penetrate markets that may not be available to US based companies. Our goal to benefit with a strategic partner based in China would be to develop our existing drug target, and widening our asset portfolio in topical drugs in dermatology in order to create a Chinese based company with an exceptional specialty pharmaceutical dermatology asset portfolio.
Celumigen Pharmaceuticals
CEO